Skip to main content
. Author manuscript; available in PMC: 2015 Sep 3.
Published in final edited form as: Thorax. 2014 Jan 24;69(6):565–573. doi: 10.1136/thoraxjnl-2013-204605

Fig 5. IFN-γ is not required for maintenance of 1018 ISS-induced disease modification.

Fig 5

Tx Protocol 2: 13 weekly RW+1018 ISS treatments were followed by 4 weekly RW exposures ± antibodies. A) BALF cytokines and serum IgE (mean ± SEM, 5 mice/group). ***P<0.001, ****P<0.0001, compared to RW. B) Antigen-specific intracellular cytokine expression (tissue pooled/group). Data representative of 2 experiments.